Orion Reports Strong H1 2026 Growth on Nubeqa Royalties and ODM-212 Progress
Event summary
- Orion's H1 2026 net sales rose 21.8% YoY to €939.3M, with Q2 up 25.2% YoY to €521.6M.
- Operating profit increased 59.6% YoY to €291.3M in H1, driven by Nubeqa® royalties and strong Branded Products growth.
- ODM-212 received Orphan Drug Designation from FDA and EU for mesothelioma treatment; Phase 2 study initiated.
- FDA approved Tessie® for canine anxiety, with U.S. commercial launch expected mid-2027.
- 2026 outlook narrowed: net sales €2B–€2.1B (previously €1.95B–€2.1B), operating profit €650M–€750M.
The big picture
Orion's strong H1 performance reflects the continued momentum of Nubeqa® royalties and strategic pipeline advancements, particularly in oncology. The company's ability to sustain growth hinges on managing royalty income volatility and progressing key clinical assets like ODM-212. With a narrowed 2026 outlook, Orion is positioning itself for further expansion in proprietary pharmaceuticals amid competitive market dynamics.
What we're watching
- Royalty Revenue Volatility
- How Nubeqa® royalty fluctuations will impact Orion's profitability, given quarterly delivery deductions and exchange rate risks.
- Pipeline Progress
- Whether ODM-212 can advance through clinical trials and secure additional regulatory designations.
- Operational Risks
- The pace at which geopolitical tensions and supply chain disruptions may affect Orion's production and profitability.